Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG103 Injection in Overweight/Obesity (Phase II)
CTR20220498Phase 2Completed
- Sponsor
- Chengdu Tianshizhen Biotechnology
- Start
- Mar 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of GX-G6 in Overweight, obesity, sponsored by Chengdu Tianshizhen Biotechnology. Started Mar 2022; status: completed.
02
Drugs
GX-G6
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on CTR20220498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220498.